VEGFA and neoplasm: For these indications, the VEGF pathway inhibitors generally show low objective response rates, but significantly slow the rate of tumor progression in patients with advanced disease leading to prolongation of progression-free survival and/or overall survival (Bruix et al., 2017; Grothey et al., 2013; Llovet et al., 2008).